.

.
marylin monroe
Showing posts with label ALCAR. Show all posts
Showing posts with label ALCAR. Show all posts

Science Round-Up Seconds: 8 Nootropics to Combat Stroke, Alheimer's & Co and Boost Cognitive Performance. Plus: 7 Rarely Thought of Side Effects of High Dose Glutamine.

Effects of infusion times on phenol content of black tea (Ramalho. 2012)
If you have already listened to the podcast of yesterday's Science Round-Up on the Super Human Radio Website (click here if you haven't and wan't to know what the following is all about), I suppose you will not mind that I compiled some of the complex information about "optimal" tea brewing in the illustration to the right (based on Ramalho. 2012). The colored arrows indicate the time-points at which the given compounds in the tea achieved peak values. The exact time point is also given in minutes, so that a 9' in front of the green caffeine and on the left to the green arrow pointing at the 9 min point tells you "it took 9 minutes for the caffeine content to reach it's maximum in the British tea". The graph in the background shows the catechin concentration depending on the infusion time.

Cholinergenic nootropics - What a recent review says

I guess some of you will probably have heard about piracetam or lecithine as purported enhancers of cognitive function. According to a recent review in the Journal of Experimental Pharmacology those two are yet not the most prosing agents:
    Eggs are rich in choline which is an essential nutrient and was abundant in the classic BB diets (rear more)
  • Piracetam: no cerebroprotective effects in patients who have open heart surgery, but does help on non-open cardiopulmonary bypass surgery (Holinski. 2008), beneficial effects in response to cerbrovascular and cognitive disorders traumatic origin (Malykh. 2010), intravenous piracetam can prevent cognitive deficits in response to anesthesia (Fesenko. 2009)
  • Lecitin: does not improve cognitive deficits in patients (Amenta. 2011; Parnetti. 2007)
More promising "nootropics" - specifically in view of what most people do actually expect, when they buy such products.
  • Oxiracetam: improves cognitive performance except for patients with dementia (Malykh. 2010)
  • Citocoline: general neuroprotective effects (Alvares-Sabin. 2011), improvements in cognitive performance in healthy and patients and patients with dementia (Secades. 2010), helps with cognitive dysfunction in Parkinson's (Vale. 2008), helps with cognitive function in dementia of neurodegenerative and vascular origin (Parnetti. 2007), prevents cognitive decline after a stroke (Alvarez. 2011), improves recovery after stroke (Garcia-Cobos. 2010) 
  • Cerebrolysine: produces signifant cognitive improvements in vascular dementia (Guekht. 2011), effective for both cognitive function and behavioral symptoms in Alzheimer's (Alvarez. 2011), promising results in patients with Alzheimer's (Plosker. 2009)
And a couple of things you would not usually associate with nootropics:
  • Suggested read: Amino Acids for Super Humans on the effects and differences between the various forms of carnitine (read more).
    Acetyl-L-carnitine: improves cognitive performance in patients with encephalopathy, decreases anxiety and increases general energy and wellness, as well as fatigue and age-related cognitive deficits (Malaguernera. 2008, Liu. 2008),can reduce or block neuronal death in neurodegenerative diseases (Manusco. 2007), helps ammeliorate hyperammonemia (Cagnon. 2007)
  • Saffron extract: beneficial effects in mild to modest Alzheimer's  (Akhondzadeh. 2010)
  • DHA (fish oil): positive effects on verbal recognition memory in old subjects (Yurko-Mauro. 2010)
Interestingly, the most profound effects appear to be brought about by acetyl-l-carnitine. In that it's worth mentioning that the benefits could still be related to cholinergic mechanisms, since it has long been known that ALCAR can increase the expression of choline acetyltransferase activity in the central nervous system (Taglialatela. 1994). And the latter is, as the name implies, necessary to form the neurotransmitter acetylcholine .

    Glutamine probably not suitable for chronic high dose supplementation

    Czech scientists warn about the risks of chronic high dose glutamine supplementation. I know that many of you are still too bamboozeled by the "protein for everything and let the liver take care of any glucose demands I may have" theory, of which you could probably argue that it is the bastard child of the standard BB diet with low carb. Maybe the following recently published paper by a scientist from the Charles University in Prague can help cure this "disease" (and your cognitive problems, fatigue and brainfog).

    According to Holecek, the chronic ingestion of glutamine / glutamine enriched diets in can lead to...
    Figure 1: In the presence of high amounts of glutamine outside of the cell, the glutamine synthesis (GLN) and with it the ammonia detoxification from muscle tissue sucks (Holecek. 2012).
    "(1) Alterations in amino acid transport-as GLN shares the transporters with other amino acids, enhanced GLN intake may impair amino acid distribution among tissues and their absorption in the gut and kidneys.

    (2) Alterations in GLN metabolism-GLN supplementation may impair synthesis of endogenous GLN and enhance glutamate and ammonia production.

    (3) Alterations in ammonia transport-GLN supplementation may impair ammonia detoxification and negatively affect the role of GLN as the carrier of ammonia among tissues.

    (4) Abnormalities in aminoacidemia-increased plasma levels of GLN, glutamate, citrulline, ornithine, arginine, and histidine and decreased levels of valine, leucine, isoleucine, glycine, threonine, serine, and proline are reported.

    (5) Alterations in immune system-as GLN has immunomodulating properties, the effect of chronic GLN consumption on the immune system needs to be assessed.

    (6) Effect on tumor growth-it should be elucidated whether chronic intake of GLN increases the risk of cancer.

    (7) Effect of the withdrawal of GLN supplementation-due to the adaptive response of the organism to enhanced GLN consumption, the withdrawal of GLN may enhance the risk of health problems resulting from GLN deficiency." (Holecek. 2012)
    Remember the post on the ammonia induced peripheral and central fatigue with high dose chronic BCAAs supplementation?
    In view of the fact that some people consumer up to 40g of glutamine regularly, Holecek demands that "long-term studies should be performed" to test the side effects and evaluate whether there is any benefit at all to justify chronic consumption of a GLN-enriched diet.

    So, relying on glutamine instead of carbs, as smart as this idea appears to be in the current carbophobia, could actually make you stupid due to the disruption of the intracellular ammonia detoxification, which is not a problem in muscle only, but also in the brain.

    In the end, what we are seeing here is just another instance of a disruption in the natural balance of things. Ornithine, citrulline and arginine, for example are involved in the detoxification of ammonia via the urea cycle. They are however not the only bottleneck to the system.

    Obviously your liver and kidneys will have to handle the clearance. People with liver problems (or persons taking "supplements" or NSAIDs that may impair the liver function) are therefore particularly prone to hyperammonemic encephalopathy (Kanamori. 1996; Lemberg. 2009)

    Bottom line: Glutamine, just like everything else, in moderation and by no means so much that your body runs on glutamine as fuel. Aside from the mentioned amino acids that help the clearance of ammonia from the blood stream, taurine appears to exert a direct protective affect in the brain (Chepkova. 2006), and lactulose (a fermentable carbohydrate) can reduce the ammonia influx from ammonia producing bacteria in the gut (Vince. 1980). So if you want to wear a helmet when you bang your head against the wall, these would be suggested "take supplement B in order to counter the side effects of supplement A" - side effects of a supplement you would not even have to take, by the way (100% bro-logic ;-)

    References: 
    • Amenta F, Carotenuto A, Fasanaro G, Lanari A, Rea R, Traini E. Preliminary results of Ascomalva trial on the association of donepezil and choline alphoscerate in Alzheimer’s disease with associated cere-brovascular injury. G Gerontol. 2011;59:89–9.
    • Akhondzadeh S, Shaf iee Sabet M, Harirchian MH, Togha M. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativusin the treatment of mild-to-moderate Alzheimer’s disease. Psychopharmacology (Berl). 2010;207:637–643.
    • Alvarez XA, Cacabelos R, Sampedro C, et al. Efficacy and safety of cerebrolysin in moderate to moderately severe Alzheimer’s disease: results of a randomized, double-blind, controlled trial investigating three dosages of cerebrolysin. Eur J Neurol. 2011;18: 59–68.
    • Alvarez-Sabín J, Román GC. Citicoline in vascular cognitive impair-ment and vascular dementia after stroke. Stroke. 2011;42(Suppl 1): S40–S43.
    • Cagnon L, Braissant O. Hyperammonemia-induced toxicity for the devel-oping central nervous system. Brain Res Rev. 2007;56:183–197.
    • Chepkova AN, Sergeeva OA, Haas HL. Taurine rescues hippocampal long-term potentiation from ammonia-induced impairment. Neurobiol Dis. 2006 Sep;23(3):512-21.
    • Fesenko UA. Piracetam improves children’s memory after general anaesthesia. Anestezjol Intens Ter. 2009;41:16–21. Polish
    • García-Cobos R, Frank-García A, Gutiérrez-Fernández M, Díez-Tejedor E. Citicoline, use in cognitive decline: vascular and degenerative. J Neurol Sci. 2010;299:188–192.
    • Guekht AB, Moessler H, Novak PH, Gusev EI; Cerebrolysin Investigators. Cerebrolysin in vascular dementia: improvement of clinical outcome in a randomized, double-blind, placebo-controlled multicenter trial. J Stroke Cerebrovasc Dis. 2011;20:310–318. 
    • Holecek M. Side Effects of Long-term Glutamine Supplementation. JPEN J Parenter Enteral Nutr. 2012 Sep 18.
    • Holinski S, Claus B, Alaaraj N, et al. Cerebroprotective effect of piracetam in patients undergoing coronary bypass surgery. Med Sci Monit. 2008;14:153–15.
    • Kanamori K, Ross BD, Chung JC, Kuo EL. Severity of hyperammonemic encephalopathy correlates with brain ammonia level and saturation of glutamine synthetase in vivo. J Neurochem. 1996 Oct;67(4):1584-94.
    • Lemberg A, Fernández MA. Hepatic encephalopathy, ammonia, glutamate, glutamine and oxidative stress. Ann Hepatol. 2009 Apr-Jun;8(2):95-102.
    • Liu J. The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res. 2008;33:194–203.
    • Mancuso C, Bates TE, Butterfield DA, et al. Natural antioxidants in Alzheimer’s disease. Expert Opin Investig Drugs. 2007;16:1921–1931.
    • Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl L-carnitine (ALC) treatment in elderly patients with fatigue. Arch Gerontol Geriatr. 2008;46:181–19
    • Malaguarnera M, Gargante MP, Cristaldi E, et al. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy. Dig Dis Sci. 2008;53: 3018–3025
    • Malykh AG, Sadaie MR. Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs. 2010;70:287–31
    • Pantoni L. Treatment of vascular dementia: evidence from trials with non-cholinergic drugs. J Neurol Sci. 2004;226:67–70
    • Parnetti L, Mignini F, Tomassoni D, Traini E, Amenta F.  Cholinergic precursors in the treatment of cognitive impairment of vascular origin: ineffective approaches or need for re-evaluation? J Neurol Sci. 2007;257:264–269.
    • Ramalho SA, Nigam N, Oliveira GB, Alves de Oliveira P, Matos Silva TO, Passos dos Santos AG, Narain N. Effect of infusion time on phenolic compounds and caffeine content in black tea  Food Research International; 13 December 2012 [ahead of print]
    • Secades JJ. Citicoline: pharmacological and clinical review. Rev Neurol. 2010;52 Suppl 2:S1–S62.
    • Vale S. Current management of the cognitive dysfunction in Parkinson’s disease: how far have we come? Exp Biol Med (Maywood). 2008;233:941–951.
    • Vince AJ, Burridge SM. Ammonia production by intestinal bacteria: the effects of lactose, lactulose and glucose. J Med Microbiol. 1980 May;13(2):177-91.
    • Yurko-Mauro K. Cognitive and cardiovascular benefits of docosahexaenoic acid in aging and cognitive decline. Curr Alzheimer Res. 2010;7:190–196.

      Amino Acids for Super Humans, Part IV - Purported Ergogenics (2/3): L-Carnitine, ALCAR, LCLT, GPLC & Co.

      Image 1: Even bought in bulk,
      the carnitines are not exactly
      cheap, so you better read on
      to gather whether ALCAR,
      L-CAR, P-LCAR, L-CLT & Co
      are worth spending money on.
      Despite the fact that even my grandmother has heard of the miraculous energizing and fat-burning abilities of carnitine, most people - and even those who are buying those carnitine-enriched functional, or should I say disfunctional foods are not even aware that L-3-hydroxy-4-N,N,N-trimethylaminobutyric acid (l-carnitine) is a naturally occurring amino acid, all mammals (humans included) can synthesize from l-lysine or l-methionine in their livers and kidneys.

      Necessary co-factors for carnitine synthesis are
      • ascorbic acid (vitamin C), 
      • pyridoxine (vitamin B6), 
      • niacin (vitamin B3) and 
      • S-Adenosyl methionine (SAMe)
      Interestingly, supplementation of the EAA substrates and co-factors failed to raise carnitine synthesis and or serum levels in respective studies. Gamma-butyrobetaine, a down-stream metabolite in carnitine synthesis from lysine, on the other hand, doubled plasma, brain, kidney and liver levels of carnitine in juvenile mice; cf. Higashi. 2001).

      Note: This is the detailed transcript of my show notes to "Amino Acids for Super Humans Part IV"
      click here to download the podcast if you want to listen before / during / after you read the rest of the notes
      In view of the limited capacity for endogenous biosynthesis of carnitine, it is not very surprising that mammals obtain the heat sensitive (at 284°F ~ 140°C carnitine starts to decompose) amino acidprimarily from their diet (Vaz. 2002); and in that, it is probably no coincidence that colostrum and breast milk are particularly high in l-carnitine, as the need for this essential metabolite in the mammalian energy metabolism increases in phases of rapid growth.
      Did you know? The first soy-based baby formulas were low in carnitine, so that neonates who were fed respective products had 1/3 lower carnitine levels than babies who were breast-fed or received milk-based products. Even in the absence of symptoms of overt carnitine deficiency, sub-optimal carnitine levels put these children at risk of early or late metabolic complications (Olson. 1989). Consequently, almost all soy-based infant formulas are enriched with l-cartinine, today.

      Vegetarians and Vegans generally have lower plasma carnitine levels
      Table 1: Amount of carnitine in food;
      meat, fish and dairy are particularly
      good sources of dietary l-carnitine
      (data adapted from wikipedia.org)

      That's unfortunate news for all vegetarians and vegans out there, because as the data in table 1 shows, meat, fish and dairy are the richest dietary sources of l-carnitine. "Omnivorous humans generally ingest 2-12 µmol of carnitine per day per kg of body weight" (Vaz. 2002), which is up to 10x the estimated amount of our endegenous production (1.2µmol /kg/day). So that 75% of the well-stocked carnitine stores of meat-eaters come from dietary, and only 25% from de novo biosynthesis. Needless to say that, with an average daily carnitine intake of <0.1µmol /kg body weight, vegetarians and vegans are usually significantly lower than those of their omnivores fellow men (Rebouche. 1992).

      Symptoms of overt carnitine deficiency, such as cardiomyopathy,
      hepatomegaly, myopathy, recurrent episodes of hypoketotic

      hypoglycaemia, hyperammonaemia and failure to thrive have yet not been observed in the absence of CDSP (primary carnitine defiency), a pathology that has been mapped to human chromosome 5q and is characterized by excessive renal and intestinal wastage of carnitine.
      Attention Atkins dieters! In a German study (Liebhaber. 2006) the long-term effects of ketogenic diets on epileptic children, carnitine deficiency was detected in 57% of the patients who did not receive supplemental l-carnitine. There was a large interpersonal variety as far as the onset of carnitine deficiency was concerned. On average subjects developed carnitine defiencey after about 32 weeks, one subject was however carnitine deficient after only two days and one subject maintain sufficient carnitine levels for 248 weeks before carnitine deficiency was diagnosed. These observations stand in line with results of Stadler et al. (Stadler. 1999) who had previously established that a high fat intake increases carnitine excretion. Taken together, this data suggests that people who follow a high fat (not the high protein low carb diet everybody is on these days) would generally benefit from carnitine supplementation.

      How carnitine facilitates "fat-burning"

      Illustration 1: Carnitine is like the man who
      shovels the coal. It's just a small wheel in the
      mitochondrial fat burning machinery. Without
      lipolytic activity (= free fatty acids floating aroun) and
      a sufficient number of properly functioning
      mitochondria, increased carnitine levels
      won't translate into fat loss (picture in the back-
      ground from Ptak Science Books. 2009)
      The previous remarks on potentially low carnitine levels suggest the assumption that their diet puts this group of people at risk of high triglyceride levels, obesity and all other sorts of metabolic pathologies related to suboptimal fatty acid oxidation. There is however very little evidence that plasma l-carnitine is - under normal conditions - rate limiting in mitochondrial beta-oxidation. If you think of coal-fired steam engines of the Titanic, would the ship have been faster and thus be able to take the safer route and still win theBlue Riband of the Atlantic if there had been more workers to fire up the ovens? Probably not, because the engines were already running at full throttle... the same is true for your mitochondria, just because there is an overabundance of carrier molecules that does not mean that your "ovens",... pardon me..., your mitochondria will be able to oxidize more fat.

      The commonly touted "fat burning" effects of l-carnitine (and all other forms of carnitine) thusly belong to the realms of advertismental oversimplifications, or should I say frauds? Even taken poundwise carnitine by itself will neither empty, nor burn the contents of a single of your unaesthetic fat cells. On the other hand, a profoundly lowered carnitine levels as they were reported for elderly and obese patients by Noland et al. (Noland. 2009) could lead to or exasperate existing weight problems by compromising the transport of fatty acids from the cytosol, i.e. the intracellular fluid, into and back out of the mitochondria.

      Figure 1: Free and bound (esterified) carnitine content in mg/kg of different meat products
      (data adapted from Seline. 2007)

      In and out that's the way things have to go

      Image 2: Lipofuscin accumulation (fine
      brown / yellow granular pigment)
      in liver cells (photo by Nephron).
      The latter, the transport of partly oxidized, "damaged fats", so called lipofuscins out of the mitochondria, may in fact be about as important for your overall metabolic health as the well-known transportation of esterified fatty acids into the mitochondria. Mitochondrial malfunction and failure aside, a way more visible effect of lipofuscin accumulation are the brown stains on old peoples skin. Of greater significance are yet the negative effects of lipofuscin depositions in the brain, which have been shown to be ameliorated by acetyl-carnitine supplementation (Kohjimoto. 1988). And it is likely that many of the established benefits of (acetyl-)l-carnitine supplementation stem from the clearance not the the entrance of fatty acids into the cells.

      Inter-cellularly, carnitine also functions as a temporary buffer for the unused acetyl-CoA. The accumulation of respective acyl-carnitines within the mitochondrion, which goes hand in hand with a depletion of unbound l-carnitine that would faciliate the transport of fatty acids into the mitochondria, has been implicated as one of the confounding factors in the etiology of the metabolic syndrome. 

      Figure 2: Simplified illustration of the underlying mechanism of carnitine mediated fatty acid transport in and out of the mitochondrion (The AOCS Lipid Library)

      L-Carnitine as a selective glucocorticoid receptor modulator & useful tool in hyperthyroidism

      Beside its effects on mitochondrial health, l-carnitine also exhibits anti-inflammatory properties by directly interacting with glucocorticoid receptors on immune cells (Manoli. 2006). In experiments Manoli et al. conducted back in 2006, l-carnitine in a glucocorticoid-like fashion "suppressed the lipopolysaccharide-stimulated release of tumor necrosis factor α and interleukin-12 from primary human monocytes". Despite its ability to stimulate glucocorticoid receptors (GR), and to reduce binding of the cortisol analogue 3H]-dexamethasone to GRs, LCAR apparently lacks the deleterious side effects corticosteroids have on other organs/tissues in the human body.
      Moreover, a study by Benvenga et al. in which women received supraphysiological doses of the synthetic thyroid hormone levothyroxin (T4) to induce symptoms of hyperthyroidism confirmed previous observations that l-carnitine even at doses as low as 2-4g/day "antagonizes hyperthyroidism-related [...] symptoms and biochemical responses of thyroid hormone target tissues". Data from cell culture experiments suggest that it is the property to inhibit T3 and T4 entry into cell nuclei, which it at the heart of the anti-(hyper-)thyroid effect of l-carnitine, since l-carnitine supplementation does not substantially affect thyroid hormone levels or radioactive iodine uptake by the thyroid.
      Did you know? Both full-blown hyper- as well as hypothyroidism have been associated with muscular carnitine depletion (Sinclair. 2005), as a consequence of insufficient synthesis (hypo-) and increased usage (hyper-) of carnitine.
      In that, it is interesting to note that, vice-versa, thyroid hormone also influences the rate of carnitine synthesis (Galland. 2002), which, again, brings up the idea of tightly regulated, feedback-control mechanisms intended to keep the metabolic rate (including the mitochondrial beta oxidation of fatty acids) in a narrow physiological range, so that in people with high levels of thyroid hormones (not necessarily hyperthyroidism) and increased carnitine production, or in people with low levels of thyroid hormones (not necessarily hypothyroidism) and decreased carnitine production the respective ratios of carnitine / thyroid hormone could lead to similar cellular T3 / T4 uptake in the presence of fundamentally different serum levels of these hormones.

      Carnitine intake and clearance - does supplementation make sense at all?

      In healthy human beings, on the other hand, the main regulatory mechanisms take place in the kidney and a basic understanding of the relation of carnitine intake to urinary loss is of fundamental importance for anyone who does not want to feed his expensive carnitine supplements to sewer rats.
      Figure 2: Free and bound (esterified) carnitine content in mg/kg of different milk products
      (data adapted from Seline. 2007)

      In general, dietary l-carnitine has a bioavailability of 54%-84% and is thusly much better absorbed than supplemental carnitine in powdered or capped form, for which Rebouche et al. report a bioavailability of meager 14%-18% (Rebouche. 2006). Ideally, you would thus get about 1.28g of carnitine from 1kg of Kangaroo steak, which turns out to be by far the best source of dietary l-carnitine.
      Note: According to the data from Rebouche et al. you wanted to get the same 1.28g of carnitine from a supplement, instead of a 3-4 dilicious steaks, you would  have to consume 7-9g of supplemental carnitine in pill or capsules for the same amount of l-carnitine to hit your blood stream!
      A vegan, who abstains from eating meat, fish and dairy, on the other hand, would have to eat his share of 60kg of mushrooms to get an equal amount of 1.28g of carnitine. Although the act of eating 60kg of mushrooms would already border the supernatural, the of 320kg of carrots you would have to eat, alternatively, are merely hypothetical.
      Figure 3: Free and bound (esterified) carnitine content in mg/kg of different mushroom, vegetable and fruit products
      (data adapted from Seline. 2007)
      Unfortunately things do not turn out to be that easy as the above calculations would suggest, because, as we physicists use to say, bioavailibilty B(m, C, F) "is a function of body weight m, carnitine availability C and the form of carnitine F" and thus depends on how much you weight, how much carnitine you eat in a single sitting, how much carnitine is already floating around in your blood stream and what form of carnitine (free l-carnitine or esterified carnitines, such as acetyl-l-carnitine or (glycine-)propionyl-l-carnitine, you ingest. Add to that some interpersonal variability and plot the total ingested and absorbed amounts of l-carnitine from a previous study of Rebouche et al. (Rebouche. 1999) in a graph and you get something that looks like this:
      Figure 4: Total ingested (full bars) and absorbed (blue part of the bar) amount of dietary carnitine in mg/kg body weight
      (data adapted from Rebouche. 1999 & Rebouche. 2006)
      It's quite obvious that - despite all interpersonal variety among the 12 test subjects - the relative amount of carnitine that actually hits the circulation decreases with increasing amounts of carnitine in the diet.
      Did you know that multiple small doses of carnitine are way superior to a single large dose if your aim is to persistently increase serum carnitine levels? In contrast to Rebouche et al. (Rebouche. 2006), who achieved relatively stable carnitine levels >50% above baseline by having their subjects take their 2g of carnitine in three divided doses (at 8am, 12pm, and 6pm) trials using a single, large bolus of l-carnitine (orally and even intraveniously) did not produce sustainable elevations in plasma carnitine levels. Furthermore, the addition of carbohydrate (96g glucose in addition to 3g l-carnitine/day) and the concomitant insulin release have been found to decrease uriniry carnitine clearance, or, converesely, increase carnitine retention by ~40% (Stephens. 2007).
      The decreased absorption of dietary carnitine from the gut goes hand in hand with a decreased reabsorption of  carnitine in the kidneys. At low to normal serum carnitine levels the latter conserve 90-99% of the circulating carnitine. When carnitine levels increase, however, the clearance rate increases way beyond the 1-3 mL/min that would leave your body in the form of urinary losses under "normal" circumstances. Thusly, increased carnitine levels, as they are the result of an intravenous infusion of 0.5g of carnitine, return to baseline in less than 12h, with a rapid decline (-80%) in the first hour after administration. Whole body turnover, i.e. the "renewal" of creatine stores, in slow (muscle) and fast turnover (liver, kidney, and other tissues) stores is estimated to take about 38-119h (Rebouche. 2006).

      On the different forms of carnitine

      The absorption issue immediately reminds me of the bro-scientific mambo-jambo about the bioavailability of different forms of carnitine you can find wherever L-CAR, ALCAR, P-LCAR, LCLT & Co are sold.  In most cases the the individual bioavailibility appears to depend on the venue the respective vendor will get from the different forms of carnitine. In that, supplement manufacturers cash in on the lack of scientific studies comparing the absorption kinetics of the various commercially available forms of carnitine in a single objective model. In this context it is also noteworthy that both commercially available carnitine-esters, i.e. acetyl-l-carnitine (ALCAR) and (glycine-)propionyl-l-carnitine (PLCAR, (G)PLC), are no invention of the supplement industry, but naturally occurring forms of carnitine, the pharmacokinetics of which have been studies by Cao et al. after oral administration of 2g of l-carnitine to 12 healthy volunteers (Cao. 2009).
      Table 2: Pharmacokinetics of l-carnitine (L-CAR), acetyl-l-carnitine (ALCAR) and propionyl-l-carnitine (PLC) after oral administration of 2g of l-carnitine to 12 healthy volunteers (data adapted from Cao. 2009)
      As it was to be expected both, the maximal, as well as the absolute plasma concentration of l-carnitine of l-carnitine are greater than that of its esters. Yet despite the sudden spike in l-carnitine levels, the clearance rate for ALCAR and PLC were greater. Conversely, the carnitine-esters have a -40% (ALCAR) and -57% shorter half-life than the free form of carnitine. In that, the high 24-h urinary excretion of ALCAR, which equals about 2x the area under the curve suggest that both long PLC esters that have previously been broken down to shorter acetyl-esters, as well as "used" and thus esterified l-carnitine are excreted as acetyl-l-carnitine.

      The results of Cao et al. stand in line with findings of Eder et al. (Eder. 2005), who used a pig model ( which is pretty reliable when it comes to modeling the human digestive system) to estimate the bioavailability of various L-carnitine esters (acetyl-L-carnitine and lauroyl-L-carnitine) and salts (L-carnitine L-tartrate, L-carnitine fumarate, L-carnitine magnesium citrate) and found that
      AUC [aera under the curve] values, calculated for the time interval between 0 and 32 hours, for both free and total carnitine were similar for base of free L-carnitine and the three L-carnitine salts (L-carnitine L-tartrate, L-carnitine fumarate, L-carnitine magnesium citrate) while those of the two esters (acetyl-L-carnitine, lauroyl-L-carnitine) were lower.
      In that, it is of particular interest that l-carnitine-l-tartrate (LCLT), which is heavily promoted as the "best" carnitine supplement, did in fact "yield a higher plasma free carnitine AUC value for the time interval between 0 and 3.5 hours than [any] of the other compounds." The faster absorption of LCLT aside, the data of this (unfortunately) unique study would suggest that the fancy "L-carnitine salts have a similar bioavailability" as the way cheaper free form of carnitine (l-carnitine) and both appear to be better absorbed than any of the l-carnitine esters .
      Did you know? Gram per gram the tartrate salt of carnitine (LCLT) provides only 40% carnitine. If, for example, you wanted 2g of pure carnitine, you would have to take 5g of LCLT.

      Acetyl l-carnitine the one and only (?) brain booster

      In the case of ALCAR, for example, it is well established that its oral bioavailability is decreased due to increased hydrolysis. Oral bioavailability, on the other hand, is only one of the attributes the addition of the acetyl ester to the free form of carnitine changes. For example, it is often cited that ALCAR would be the only form of carnitine that is able to pass the blood-brain-barrier (BBB) in mammals. This statement is simply false! While it is true that the acetylated form of carnitine passes enters the brain more easily, i.e. it takes lower concentrations outside the barrier to achieve the same levels of carnitine within the brain, the difference in K(m) values, which area a measure of the concentration of substrate required to produce 50% of the maximal uptake, is only 5% (K(m)Alcar=31.3 vs. K(m)Carn=33.1, cf. Kido. 2008).

      Anyway, at least those of you who have some sort of cognitive / neurological problem, probably won't really care if ALCAR is actually the only, or maybe just the favorable form of carnitine to treat neurological diseases, as long as it will help mitigate your problems - and indeed, ALCAR appears to be a formidable "brain nutrient" which has been used succesfully in a variety of brain-related clinical conditions (Alternative Medicine Review. 2010):
      • Alzheimer's disease
      • Depression
      • Attention deficit / hyperactivity disorder (ADHD) and Fragile X Syndrome
      • Peripheral (diabetic, antiretroviral and chemotherapy-induced) neuropathy
      • Cerebral ischemia and reperfusion
      • and others
      The underlying mechanisms of action most likely are:
      • Increasing neural energy production
      • Protecting neurons from toxins
      • Maintaining neuron receptors
      • Increasing availability of the neurotransmitter acetylcholine
      • Decreasing accumulation "damaged fats" (lipofuscins) in brain tissue
      If administered orally, dosages usually range from 2.0-5.0g of ALCAR, mostly taken in divided doses. Reports on side effects are scarce, and generally limited to agitation, nausea and vomiting, so that ALCAR is generally considered safe, even wit long-term administration  (Spagnoli. 1991).
        (Glycine) propionyl l-carnitine the one and only (?) nitric oxide booster

        Image 3: Molecular structure
        of the bulky 3-Propanoyloxy-
        4-(trimethylazaniumyl)butanoate
        molecule which usually goes by
        the name Propionyl-L-carnitine, or
        its abbreviations PLC or PLCAR.

        GPLC, i.e. glycine propionyl l-carnitine certainly is the fancier of the two readily available carnitine esters. I mean, who cares about brain health, if GPLC promises huge pumps? The target group of the colorful ads in the bodybuilding magazines probably doesn't. Yet while studies from the Department of Health and Sport Sciences at the University of Memphis (Bloomer 2007; Bloomer. 2009), the Department of Exercise Science and Health Promotion at the Florida Atlantic University (Jacobs. 2009) support the claim that the combination of glycine and propionyl l-carnitine can increase nitric oxide production, decrease lactate accumulation and increase performance in high intensity exercises such as sprinting, the exact underlying mechanism remains questionable. Especially in view of the fact that Bloomer et al. (Bloomer 2007) administered glycine (1g) and the carnitine ester PLC (3g) in an unbound form, further investigation, whether co-administration of glycine and l-carnitine would not produce similar, yet more cost effective results, are warranted.
        Note: I assume, you have also heard of the paradoxical effect 4.5g of GPLC had on sprint performance in a 2010 follow-up study of Jacobs et al. (Jacobs. 2010). In contrast to what the scientists had expected based on previous results (Jacobs. 2009), long-term supplementation of a high dose (4.5g vs. 1.5g) of glycine propionyl l-carnitine did not only fail to improve sprint performance beyond what was achieved with 1/3 of the dosage, the huge pump, the athletes were complaining about, even compromised their performance. If you are an athlete, exceeding a dose 1-2g of GPLC per day would thus be more than a waste of money, it could actually cost you your victory. Remember: With most supplements taking more does not equal greater benefits!
        L-carnitine l-tartrate the one an only (?) testosterone booster

        Image 4: "Supported" studies make
        LCLT highly marketable (Lonza, Inc)
        Based on what you (should) have learned from the previous paragraphs, you should not be surprised to hear that l-carnitine l-tatrate at dises of 5g (equiv. to 2g of carnitine), just as his "brethren" l-carnitine, acetyl- and propionyl l-carnitine may be considered a scientifically proven ergogenic. Ester (ALCAR, PLC) or salt (L-carnitine L-tartrate, L-carnitine fumarate, L-carnitine magnesium citrate), after all, its all carnitine... that being said, I do not question any of the highly marketable results Kraemer, Volek and the other scientists from the Human Performance Laboratory, Department of Kinesiology at the University of Connecticut have produced. I am just asking myself, why none of these studies compared the expensive tartrate salt, L-Carnipure® tartrate, the scientists received along with research grants from Lonza, Inc, to the much cheaper non-patented free form of carnitine. You do not have an answer, do you?
        Did you ever think of the remote possibility that the "subtle yet significant" effects l-carnitine l-tartrate had on androgen receptor expression and testosterone in the heavily cited 2006 study by Kraemer et al. (Kraemer. 2006), may come from the tartrate and not the carnitine? Me neither, but the idea Owner (pseudonym) from the Mind&Muscle boards brought up, back in the days, is not totally devious. Join the smartest BB-community on the net and revive the discussion, if you will!

        Conclusion

        Do you remember? This write-up started out with the purported fat-burning effects of carnitine, established that carnitine is a necessary, but not sufficient co-factor in mitochondrial beta oxidation and clearance of fatty acid, elaborated on the metabolic and neurological health benefits of carnitine and concluded on the true ergogenic value of what turned out to be a whole group of quite expensive amino acids, the use of which you should take into consideration only after you got your (carnivorous) diet, your training regimen and your basic supplement protocol (protein, creatine + facultative EAA/BCAA) in check.

        Mitochondrial Super Food: R-ALA, Acetyl-L-Carnitine, Biotin, Nicotinamide (B3), Riboflavin (B2), Pyridoxine (B6), Creatine, CoQ10, Resveratrol & Taurine Optimize Mitochondrial Function.

        From China, the biggest (and cheapest) producer of raw materials for dietary supplements comes a study (Sun. 2011) on the effectiveness of a mitochondrial nutrient combination on performance and mitochondrial biogenesis in exhaustively exercised rats, which may well have consequences on the number of items on your next supplement shopping list.

        For 4 weeks, Sun et al. supplemented exhaustively exercising rats with a combination of R-a-lipoic acid, acetyl-L-carnitine, biotin, nicotinamide, riboflavin, pyridoxine, creatine, CoQ10, resveratrol and taurine (cf. table 1)
        Table 1: Ingredients of the "mitochondrial nutrient supplement";dosage used in rat study (data adapted from Sun. 2011); and calculated human equivalent doses 

        This nutrient combination had beneficial effects on standard markers of exercise induced oxidative stress and muscular breakdown. Specifically, it "significantly inhibited the increase in activities of alanine transaminase, lactate dehydrogenase and creatine kinase". The supplementation protocol also had beneficial effects on antioxidant status reversing increases in malondialdehyde and inhibiting the decrease in glutathione S-transferase and total antioxidant capacity in plasma. It also suppressed the elevation of reactive oxygen species in the spleen and thus protected splenic lymphocytes from apoptosis [cell death].

        These effects were accompanied / mediated by significant increases mitochondrial biogenesis, evidenced by increases in
        [...] the protein expression of mitochondrial complexes I, II and III, mtDNA number and transcription factors involved in mitochondrial biogenesis and fusion in skeletal muscle.

        Taken together these results underline that proper nutrition, not only on a macroscopic, but also on a microscopic level, is of paramount importance to exercise performance and metabolic health. Interestingly, the amount of the supplemental "mitochondrial nutrients" used in this study is not even exorbitantly high. In fact, the human equivalent doses (cf. table 1) would be easily attainable by a nutrient-rich diet and some cheap and readily available supplements.

        Carnitine Shoot-Out: L-Carnitine, Acetylcarnitine, Propionyl- Carnitine - Which One Has the Highest Bioavailability? Plus: 2g LCAR Contain More Carnitine Than 2g ALCAR or PLCAR

        What if we don't know what's most bioavailable? Does it really matter?
        After years of being labeled as the supplemental non-starter #1, carnitine is got back on the radar of the average and extraordinary gymrat. The reasons are obvious - at least if you read the following SuppVersity articles: "Carnitine Wards Off Fat Gain by Increasing Fatty Acid Oxidation and Total Energy Expenditure" | more, "Carnitine as Repartitioning Agent?" | more, "L-Carnitine Increase Expression of Genes Implicated in Fatty Acid Oxidation, Glucose & Lipid Metabolism" | more. There have been quite a few impressive studies on the benefits of carnitine, lately, and their publication attracted a significant amount of attention in the bodybuilding, health and fitness community.

        The question that remains, though, is: Which of the various forms of carnitine works best? Basically that's also what a group of scientists from the University (Hospital) Bern had in mind, when they put gavaged they put their mice on "supplement regimen" containing 2 mmol/kg/day carnitine from plain l-carnitine (LCAR), acetyl-l-carnitine (ALCAR), or propionyl-l-carnitine (PLCAR) for 4 weeks.
        Rel. Carnitine content of l-carnitine, acetyl-l-carnitine (ALCAR), propionyl-l-carnitine (PLCAR) and l-carnitine-l-tartrate (LCLT)
        Millimol vs. grams - for the carnitines that's a tremendous difference! I know that most of you will be annoyed when they get dosing regimen in millimoles instead of grams, milligrams of micrograms. That's understandable, 'cause it's inconvenient to have to check the molar mass of the given compound, grab the next best calculator and type 2 × 10-3mol * 161.199g/mol to eventually find out that the daily dose we are talking about here is 322.398mg/kg for the mice and thus ca. 26mg/kg or 2g for a human being with a body weight of 80kg (learn how to calculate HEDs).

        The inconvenient moles do yet have one major advantage: We don't get into trouble, when we compare "compound molecules" such as the acetyl-carnitine. ALCAR is after all produced by combining L-carnitine and acetyl-CoA and does therefore have a ca. 21% higher molecule mass than the "original" molecule. Practically speaking 500mg ALCAR caps do thus contain 21% less actual carnitine that the basic l-carnitine caps of your neighbor. Aside from increasing the molecular weight, the acetyl-CoA attachment does yet also change it's biological function - in other words: You may get the most carnitine for your money if you buy l-carnitine caps, but whether that equals the most "bang for your buck", is a whole different (non-mathematical) question.
        Between week 1 and 2 of supplementation, the mice spent 24 h individually in metabolic cages with supplemented water and food ad libitum. During this period, 24-h urine was collected to assess the excretion of carnitine and acylcarnitines.
        After 4 weeks of supplementation, the mice were submitted to an exhaustive exercise on a treadmill, after which they were anesthetized to take the muscle samples that were used to measure the carnitine content you see in Figure 1.
        What you cannot see in Figure 1 is that the mice gained an identical amount of weight, and that there were minimal, due to intra-group difference yet statistical non-significant differences in water and thus effective carnitine intake between the LCAR, the ALCAR and the PLCAR groups (it's worth noting that all rodents on carnitine consumed 13-45% more water, so if you feel freaking thirsty, when you're "on" carnitine that may be a natural reaction to the increased). Likewise not shown is are the effect of carnitine on the skeletal muscle architecture, i.e. the ratio of fast-twitch glycolytic and slow-twitch oxidative fibers. The latter remained unchanged - the "specific trophic effect on type 1 fibers which are characterized by an oxidative metabolism" (Spagnoli. 1990) about which Spagnoli et al. speculated in 1990 was absent.
        No changes in Skeletal muscle oxidative capacity! In spite of the fact that this is one of the classic promises of carnitine supplementation, the scientists did not observe significant difference in oxygen uptake between animals treated with carnitine or acylcarnitines and control animals and conclude: "These findings indicate that mitochondrial content and capacity (the activity of complexes I, II, and IV of the respiratory chain) remained unchanged in the supplemented compared to the control group" (Morand. 2013)
        What you do see in Figure 1, on the other hand, may be misleading, because the existing differences in total carnitine after 4 weeks on the different forms of carnitine were non-significantly increased compared to the control group, so that the bioavailability, the researchers calculated based on the tissue accumulation and urinary excretion of various forms of carnitine were identical, i.e. l-carnitine - 19.8%, acetyl-l-carnitine - 18.6%, propionyl-l-carnitine - 19.1 % (see Figure 3).

        It is not unlikely that the absence of significant differences in bioavailability is a direct result of the fact that the acylcarnitines and propionyl-l-carnitine were fully and partially hydrolyzed before reaching the systemic circulation, respectively. Whether there really is a difference to humans, as the scientists claim appears questionable, because the difference between Morand et al.'s rats and Eder's pigs, on the one hand, and the 11 Alzheimer's patients in Parnetti et al. (1992) could well be brought about by age-/health-, and not species-specific differences.

        Preformance, not tissue carnitine concentrations count, right?

        In the end this may not even be that important given the fact that supplementing with all three forms of carnitine associated with a lower plasma lactate concentration and a better maintenance of the glycogen stores in white skeletal muscle after exhaustive exercise (Figure 2).

        As the researchers point out, similarly lowered post-exercise blood lactate concentrations have recently also been reported in humans treated with 4.5 g glycine propionylcarnitine before exercise (Jacobs. 2009).
        "These findings indicate that the animals supplemented with carnitine or acylcarnitines tolerated exhaustive exercise metabolically all in all better than the control animals. This may at least partially explain the beneficial effects of carnitine supplementation on physical recovery after intense exercise." (Morant. 2013)
        The fact that this occured in the absence of extreme increases in the intramuscular carnitine stores supports a hypothesis that has been put forward by Rebouche et al. in a review about the pharmacokinetics and metabolism of carnitine and acetyl carnitine (Rebouche. 2004), where the researchers asked the question whether an increased carnitine content in target tissues is even necessary for a pharmacological effect of carnitine or whether an increased exchange between the plasma and tissue carnitine pools could be sufficient. Based on the results of the study at hand, the latter appears pissible, if not likely, "the molecular mechanisms responsible for this effect remain speculative, however" (Morant. 2013). Possible explanations Morant et al. propose are:
        • The export of potentially toxic acyl groups from skeletal muscle, as shown in patients on hemodialysis supplemented with carnitine (Vernes. 2006).
        • An effect of carnitine and/or acylcarnitines on capillary endothelial cells, possibly resulting in vasodilation and improved skeletal muscle perfusion and nutrient supply during high-intensity exercise (Jacobs. 2009).
        In the end it is thus likely that you can benefit from the provision of 2-5g of carnitine, irrespective of the form you chose (this goes only for LCAR, ALCAR and PLCAR, to make a similar statement about LCLT, which has - among other things - been shown to increase testosterone receptor expression, is a whole different animal).
        Bottom line: Despite the pathetic increases in muscle carnitine, the non-existent effects on body weight, carcass and muscle composition and the significant loss of the orally administered carnitine, the study at hand does provide evidence of the ergogenic effects of carnitine. The maintenance of white skeletal muscle glycogen stores, which would actually suggest an increase in fatty acid oxidation, although the corresponing mitochondrial enzymes weren't elevated, the improved lactate concentrations and the minimal, statistically non-signficant, but measurable increases in time to exhaustion are after all ergogenic effects that could provide a metabolic advantage to any trainee.

        Figure 3: Comparison of l-carnitine kinetics of  in rodents and humans in response to chronic and acute oral suppl., respectively (Coa. 2009; Morant. 2013)
        Whether this metabolic advantage is relevant for the average trainee is yet about as questionable, as the question: "Plain carnitine, ALCAR or PLCAR, what's the best form of carnitine to take?" Based on the results of the study at hand, it would appear that it does not really matter.

        If we do yet look back at Table 2 in the Amino Acids for Super Humans" article on carnitine, or the bottom of Figure 3 in this article, it would yet appear as if the results Morant et al. present in their latest paper in the European Journal of Nutrition only support the notion that ALCAR and PLCAR, both of which are sold as a form of "improved" carnitine by the supplement industry, are not the go-to forms of carnitine for the average physical culturist. For him or her, if anything, buying plain l-carnitine over at a bulk supplier of his / her trust would probably be the best option.
        Reference:
        • Eder, Klaus, et al. "Free and total carnitine concentrations in pig plasma after oral ingestion of various L-carnitine compounds." International journal for vitamin and nutrition research 75.1 (2005): 3-9.
        • Parnetti, L., et al. "Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer type." European journal of clinical pharmacology 42.1 (1992): 89-93.
        • Rebouche, Charles J. "Kinetics, Pharmacokinetics, and Regulation of l‐Carnitine and Acetyl‐l‐carnitine Metabolism." Annals of the New York Academy of Sciences 1033.1 (2004): 30-41.
        • Spagnoli, Luigi G., et al. "Morphometric evidence of the trophic effect of L-carnitine on human skeletal muscle." Nephron 55.1 (1990): 16-23. 
        • Vernez, Laurence, et al. "Effect of L-carnitine on the kinetics of carnitine, acylcarnitines and butyrobetaine in long-term haemodialysis." Nephrology Dialysis Transplantation 21.2 (2006): 450-458.
        • Wang, Yong-Xu, et al. "Regulation of muscle fiber type and running endurance by PPARδ." PLoS biology 2.10 (2004): e294.